Advertisement

Pharmaceutical Research

, 35:228 | Cite as

In Vitro Skin Retention and Drug Permeation through Intact and Microneedle Pretreated Skin after Application of Propranolol Loaded Microemulsions

  • Megan N. Kelchen
  • Nicole K. Brogden
Research Paper
  • 185 Downloads

Abstract

Purpose

Topical beta-blockers are efficacious for treating infantile hemangiomas, but no formulations have been specifically optimized for skin delivery. Our objective was to quantify skin concentrations and drug permeation of propranolol (a nonselective beta-blocker) after application of microemulsions to intact and microneedle pretreated skin.

Methods

Four propranolol-loaded microemulsions were characterized for droplet size, surface charge, conductivity, pH, drug solubility, and drug release. Skin concentrations and drug permeation through skin were quantified using LC-MS. Skin-to-receiver ratios were used to compare the microemulsion formulations to a drug-in-PBS solution.

Results

Propranolol solubility was significantly greater in microemulsions vs PBS. Cumulative drug release from the microemulsions over 24 h ranged from 13 to 26%. Skin concentrations and drug permeation through intact skin was significantly higher from PBS; however, the skin-to-receiver ratios were significantly higher for water-rich microemulsions compared to PBS or surfactant-rich microemulsions. Microneedle pretreatment significantly increased skin concentrations for all formulations. Skin-to-receiver ratios significantly increased after microneedle pretreatment for surfactant-rich microemulsions.

Conclusions

Microemulsion formulation can be altered to elicit different drug delivery profiles through MN-treated skin. This could be advantageous for maximizing local skin drug concentrations and improving dosing schedules for infantile hemangioma treatment.

KEY WORDS

infantile hemangioma microemulsion microneedle propranolol skin 

ABBREVIATIONS

ER

Enhancement ratio

IH

Infantile hemangioma

MN

Microneedle

Notes

ACKNOWLEDGMENTS AND DISCLOSURES

This work was supported by NIH grant R35GM124551.

References

  1. 1.
    Guy RH. Transdermal drug delivery. Handb Exp Pharmacol. 2010;197:399–410.CrossRefGoogle Scholar
  2. 2.
    Flynn G. Cutaneous and transdermal delivery - processes and systems of delivery. 4th ed. In: Banker G, Siepmann J, Rhodes C, editors. Modern Pharmaceutics. Boca Raton: CRC Press; 2002.Google Scholar
  3. 3.
    Kim YC, Park JH, Prausnitz MR. Microneedles for drug and vaccine delivery. Adv Drug Deliv Rev. 2012;64(14):1547–68.CrossRefGoogle Scholar
  4. 4.
    Zhang Y, Brown K, Siebenaler K, Determan A, Dohmeier D, Hansen K. Development of lidocaine-coated microneedle product for rapid, safe, and prolonged local analgesic action. Pharm Res. 2012;29(1):170–7.CrossRefGoogle Scholar
  5. 5.
    Shin JU, Kim JD, Kim HK, Kang HK, Joo C, Lee JH, et al. The use of biodegradable microneedle patches to increase penetration of topical steroid for prurigo nodularis. Eur J Dermatol. 2018;28(1):71–7.PubMedGoogle Scholar
  6. 6.
    Choi SY, Kwon HJ, Ahn GR, Ko EJ, Yoo KH, Kim BJ, Lee C, Kim D. Hyaluronic acid microneedle patch for the improvement of crow’s feet wrinkles. Dermatol Ther. 2017;30(6).  https://doi.org/10.1111/dth.12546 CrossRefGoogle Scholar
  7. 7.
    Milewski M, Stinchcomb AL. Vehicle composition influence on the microneedle-enhanced transdermal flux of naltrexone hydrochloride. Pharm Res. 2011;28(1):124–34.CrossRefGoogle Scholar
  8. 8.
    Gujjar M, Banga AK. Vehicle influence on permeation through intact and compromised skin. Int J Pharm. 2014;472(1–2):362–8.CrossRefGoogle Scholar
  9. 9.
    Pappinen S, Urtti A. Microemulsions. In: Dragicevic N, Maibach HI, editors. Percutaneous penetration enhancers chemical methods in penetration enhancement: Nanocarriers. Berlin, Heidelberg: Springer Berlin Heidelberg; 2016. p. 253–62.CrossRefGoogle Scholar
  10. 10.
    Heuschkel S, Goebel A, Neubert RH. Microemulsions--modern colloidal carrier for dermal and transdermal drug delivery. J Pharm Sci. 2008;97(2):603–31.CrossRefGoogle Scholar
  11. 11.
    Songkro S, Lo NL, Tanmanee N, Maneenuan D, Boonme P. In vitro release, skin permeation and retention of benzophenone-3 from microemulsions (o/w and w/o). J Drug Deliv Sci Technol. 2014;24(6):703–11.CrossRefGoogle Scholar
  12. 12.
    Amarji B, Garg NK, Singh B, Katare OP. Microemulsions mediated effective delivery of methotrexate hydrogel: more than a tour de force in psoriasis therapeutics. J Drug Target. 2016;24(2):147–60.CrossRefGoogle Scholar
  13. 13.
    Ren Q, Deng C, Meng L, Chen Y, Chen L, Sha X, et al. In vitro, ex vivo, and in vivo evaluation of the effect of saturated fat acid chain length on the transdermal behavior of ibuprofen-loaded microemulsions. J Pharm Sci. 2014;103(6):1680–91.CrossRefGoogle Scholar
  14. 14.
    Baroli B, Lopez-Quintela MA, Delgado-Charro MB, Fadda AM, Blanco-Mendez J. Microemulsions for topical delivery of 8-methoxsalen. J Control Release. 2000;69(1):209–18.CrossRefGoogle Scholar
  15. 15.
    Mitragotri S. Synergistic effect of enhancers for transdermal drug delivery. Pharm Res. 2000;17(11):1354–9.CrossRefGoogle Scholar
  16. 16.
    Zu Q, Yu Y, Bi X, Zhang R, Di L. Microneedle-assisted percutaneous delivery of a Tetramethylpyrazine-loaded microemulsion. Molecules. 2017;22(11).CrossRefGoogle Scholar
  17. 17.
    Munden A, Butschek R, Tom WL, Marshall JS, Poeltler DM, Krohne SE, et al. Prospective study of infantile haemangiomas: incidence, clinical characteristics and association with placental anomalies. Br J Dermatol. 2014;170(4):907–13.CrossRefGoogle Scholar
  18. 18.
    Leaute-Labreze C, Dumas de la Roque E, Hubiche T, Boralevi F, Thambo JB, Taieb A. Propranolol for severe hemangiomas of infancy. N Engl J Med. 2008;358(24):2649–51.CrossRefGoogle Scholar
  19. 19.
    Leaute-Labreze C, Harper JI, Hoeger PH. Infantile haemangioma. Lancet. 2017;390(10089):85–94.CrossRefGoogle Scholar
  20. 20.
    Painter SL, Hildebrand GD. Review of topical beta blockers as treatment for infantile hemangiomas. Surv Ophthalmol. 2016;61(1):51–8.CrossRefGoogle Scholar
  21. 21.
    Prausnitz MR, Langer R. Transdermal drug delivery. Nat Biotechnol. 2008;26(11):1261–8.CrossRefGoogle Scholar
  22. 22.
    Montenegro L, Carbone C, Condorelli G, Drago R, Puglisi G. Effect of oil phase lipophilicity on in vitro drug release from o/w microemulsions with low surfactant content. Drug Dev Ind Pharm. 2006;32(5):539–48.CrossRefGoogle Scholar
  23. 23.
    Ibrahim SA, Li SK. Efficiency of fatty acids as chemical penetration enhancers: mechanisms and structure enhancement relationship. Pharm Res. 2010;27(1):115–25.CrossRefGoogle Scholar
  24. 24.
    Kaur G, Mehta SK. Developments of Polysorbate (tween) based microemulsions: preclinical drug delivery, toxicity and antimicrobial applications. Int J Pharm. 2017;529(1–2):134–60.CrossRefGoogle Scholar
  25. 25.
    Kreilgaard M. Influence of microemulsions on cutaneous drug delivery. Adv Drug Deliv Rev. 2002;54(Suppl 1):S77–98.CrossRefGoogle Scholar
  26. 26.
    Williams AC, Barry BW. Penetration enhancers. Adv Drug Deliv Rev. 2004;56(5):603–18.CrossRefGoogle Scholar
  27. 27.
    Rhee YS, Choi JG, Park ES, Chi SC. Transdermal delivery of ketoprofen using microemulsions. Int J Pharm. 2001;228(1–2):161–70.CrossRefGoogle Scholar
  28. 28.
    Hua L, Weisan P, Jiayu L, Ying Z. Preparation, evaluation, and NMR characterization of vinpocetine microemulsion for transdermal delivery. Drug Dev Ind Pharm. 2004;30(6):657–66.CrossRefGoogle Scholar
  29. 29.
    Kreilgaard M, Pedersen EJ, Jaroszewski JW. NMR characterisation and transdermal drug delivery potential of microemulsion systems. J Control Release. 2000;69(3):421–33.CrossRefGoogle Scholar
  30. 30.
    Delgado-Charro MB, Iglesias-Vilas G, Blanco-Méndez J, López-Quintela MA, Marty J-P, Guy RH. Delivery of a hydrophilic solute through the skin from novel microemulsion systems. Eur J Pharm Biopharm. 1997;43(1):37–42.CrossRefGoogle Scholar
  31. 31.
    Tabosa MAM, de Andrade ARB, Lira AAM, Sarmento VHV, de Santana DP, Leal LB. Microemulsion formulations for the transdermal delivery of Lapachol. AAPS PharmSciTech. 2018;19(4):1837–46.CrossRefGoogle Scholar
  32. 32.
    Lu GW, Gao P. CHAPTER 3 - emulsions and microemulsions for topical and transdermal drug delivery A2 - kulkarni, Vitthal S. Handbook of non-invasive drug delivery systems. Boston: William Andrew Publishing; 2010. p. 59–94.Google Scholar
  33. 33.
    Changez M, Varshney M, Chander J, Dinda AK. Effect of the composition of lecithin/n-propanol/isopropyl myristate/water microemulsions on barrier properties of mice skin for transdermal permeation of tetracaine hydrochloride: in vitro. Colloids Surf B: Biointerfaces. 2006;50(1):18–25.CrossRefGoogle Scholar
  34. 34.
    Djordjevic L, Primorac M, Stupar M. In vitro release of diclofenac diethylamine from caprylocaproyl macrogolglycerides based microemulsions. Int J Pharm. 2005;296(1–2):73–9.CrossRefGoogle Scholar
  35. 35.
    El Maghraby GM. Transdermal delivery of hydrocortisone from eucalyptus oil microemulsion: effects of cosurfactants. Int J Pharm. 2008;355(1–2):285–92.CrossRefGoogle Scholar
  36. 36.
    Guy RH, Hadgraft J. Physicochemical aspects of percutaneous penetration and its enhancement. Pharm Res. 1988;5(12):753–8.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Pharmaceutical Science and Experimental TherapeuticsUniversity of Iowa College of PharmacyIowaUSA
  2. 2.Department of DermatologyUniversity of Iowa Carver College of MedicineIowaUSA

Personalised recommendations